title: LFA-1 expression in a series of colorectal adenocarcinomas.
abstract: BACKGROUND
  LFA-1 is an adhesion molecule which belongs to the β2-integrin family. Overexpression of LFA-1 in hepatic natural killer cells has been associated with increased apoptosis of neoplastic cells in colorectal cancer (CRC); moreover, studies in CRC have linked LFA-1 overexpression in neoplastic cells with vascular intrusion through adhesion to endothelial cells, thus implying a possible role in creation of metastases.
  
  
  OBJECTIVE
  We studied the expression of LFA-1 in a series of 82 patients with CRC. A standard three-step immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded tissue sections. An IgG2a anti-CD11a monoclonal antibody was used. Cases were characterized according to clinicopathological variables including sex, age, tumor localization, size, grade, Dukes stage, wall invasion, and presence of metastatic lymph nodes (mLNs) or distal metastases.
  
  
  RESULTS
  LFA-1 was expressed at the primary tumor site in 51 cases and 6/33 cases with metastatic lymphnodes. In Dukes D cases (n = 4), only one case was LFA-1(+). LFA-1 expression at the primary tumor site was associated with the absence of metastatic disease and with Dukes B stage. However, in those cases with LFA-1 expression in cancer cells in mLNs, this was associated with its expression at the primary tumor site.
  
  
  CONCLUSIONS
  The positive association of LFA-1 expression in mLNs when the primary tumor site is also LFA-1(+) could imply an adaptation advantage of this specific cellular clone to its micro-environment, predisposing it to creation of mLNs, pointing to a role for LFA-1 in creation of mLNs in CRC.
authors.affiliation: First Department of Pathology, Faculty of Medicine, University of Athens, Athens, Greece.
authors.forename: Maria G
authors.initials: MG
authors.lastname: Papas
authors.forename: Pantelis S
authors.initials: PS
authors.lastname: Karatzas
authors.forename: Ioannis S
authors.initials: IS
authors.lastname: Papanikolaou
authors.forename: Evanthia
authors.initials: E
authors.lastname: Karamitopoulou
authors.forename: Eumorphia M
authors.initials: EM
authors.lastname: Delicha
authors.forename: Andreas
authors.initials: A
authors.lastname: Adler
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Triantafyllou
authors.forename: Georgia-Heleni
authors.initials: GH
authors.lastname: Thomopoulou
authors.forename: Efstratios
authors.initials: E
authors.lastname: Patsouris
authors.forename: Andreas C
authors.initials: AC
authors.lastname: Lazaris
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary*; D000368:Aged; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D016169:Lymphocyte Function-Associated Antigen-1 / Q000378:metabolism*; D008297:Male; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D011379:Prognosis
chemical_list: D016169:Lymphocyte Function-Associated Antigen-1
references.citation: Curr Med Chem. 2008;15(10):978-90
references.pmid: 18393855
references.citation: Cancer Treat Res. 2002;107:305-29
references.pmid: 11775459
references.citation: Lancet. 2005 Jan 8-14;365(9454):153-65
references.pmid: 15639298
references.citation: J Gastrointestin Liver Dis. 2010 Jun;19(2):155-9
references.pmid: 20593048
references.citation: Immunol Rev. 2007 Aug;218:135-46
references.pmid: 17624950
references.citation: J Urol. 2002 Apr;167(4):1836-43
references.pmid: 11912444
references.citation: J Hepatol. 1999 Jul;31(1):110-6
references.pmid: 10424290
references.citation: Am J Physiol Gastrointest Liver Physiol. 2001 Oct;281(4):G1068-80
references.pmid: 11557528
references.citation: Blood. 1998 May 15;91(10):3909-19
references.pmid: 9573029
references.citation: J Cell Sci. 2003 Dec 1;116(Pt 23):4695-705
references.pmid: 14600256
references.citation: J Gastroenterol Hepatol. 2002 Oct;17(10):1084-6
references.pmid: 12201868
references.citation: Cancer Res. 2008 Feb 1;68(3):880-8
references.pmid: 18245490
references.citation: J Cell Biol. 2000 Feb 21;148(4):779-90
references.pmid: 10684258
references.citation: Lab Invest. 1998 Nov;78(11):1395-404
references.pmid: 9840614
references.citation: Curr Pharm Des. 2008;14(3):296-305
references.pmid: 18220840
references.citation: Cancer Res. 1999 Sep 1;59(17):4427-34
references.pmid: 10485493
references.citation: Blood. 2010 Aug 26;116(8):1272-9
references.pmid: 20472831